MHR
AMPH icon

Matthew Hamilton Rosenberg’s Amphastar Pharmaceuticals AMPH Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$62 – 855
2023
Q4 		$62 Hold
1
– – ﹤0.01% 897
2023
Q3 		$46 Hold
1
– – ﹤0.01% 915
2023
Q2 		$57 Buy
+1
New +$44 ﹤0.01% 930

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Matthew Hamilton Rosenberg's AMPH Position: Q1 2024 in Review

Matthew Hamilton Rosenberg sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 1 share — an estimated $62 sold.

Matthew Hamilton Rosenberg first reported a position in AMPH in Q2 2023 and held it in 3 quarters. The position peaked at $62 in Q4 2023. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

  • Matthew Hamilton Rosenberg reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Matthew Hamilton Rosenberg sold 1 Amphastar Pharmaceuticals share in Q1 2024, an estimated $62.
  • Matthew Hamilton Rosenberg first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Matthew Hamilton Rosenberg's Amphastar Pharmaceuticals position peaked at $62 in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Matthew Hamilton Rosenberg's 13F filing for Q1 2024, filed 22 Apr 2024.